臨床研究等提出・公開システム

Safety and efficacy of bio 3D nerve conduit (B3CON-01) for peripheral nerve injury; investigator-initiated clinical trials (B3CON)

Investigator-initiated clinical trials of bio 3D nerve conduit (B3CON)

Ikeguchi Ryosuke

Kyoto University Hospital

54 Kawahara-cyo,Shogoin,Sakyo-ku,Kyoto 606-8507,JAPAN

ikeguchi@kuhp.kyoto-u.ac.jp

Ikeguchi Ryosuke

Kyoto University Hospital

54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto, Japan

+81-75-366-7722

ikeguchi@kuhp.kyoto-u.ac.jp

Not Recruiting

June. 01, 2020

Interventional

single arm study

open(masking not used)

uncontrolled control

single assignment

treatment purpose

1) severed peripheral nerve injuries or a defect in the region distal to the wrist joint not caused by a congenital anomaly;
2) a defect with a length of =<20 mm in a nerve with a diameter =<22 mm
3) failed results of sensory functional tests, including the Semmes -Weinstein monofilament test and static and moving 2-point discrimination sensory functional tests (s2PD and m2PD), for dermatome distribution of the injured peripheral nerve
4) able to register in the protocol within 6 months from the day of injury
5) refused artificial nerve or autologous nerve transplantation
6) age 20-60 years
7) willingness to participate and provide informed written consent

1) peripheral nerve injury, including those in the fingers affected by infection and severe damage of accessories -including the skin, tendon, and bone- injury at multiple sites of the nerve and wide area, and direct suture-feasible
2) presence of antibodies against hepatitis B, human immunodeficiency, or human T-cell leukaemia virus
3) active infection, such as hepatitis C, syphilis (Treponema pallidum antibody-positive in serological tests for syphilis), and human parvovirus B19
4) a history of allergy or anaphylaxis reaction to a component(s) of the clinical trial products, such as aminoglycoside antibiotics, polyene macrolide antibiotics, bovine serum, and/or metal(s)
5) one of the following complications, including cardiovascular disease(s), diabetes mellitus, stroke (including history), cervical spondylosis, cervical myelopathy, polyneuropathy, Guillain-Barre syndrome, amyotrophic lateral sclerosis, peripheral circulatory failure, rheumatoid arthritis, collagen disease, depression, schizophrenia, automatic neuropathy, or dementia
6) malignant disease and/or medical history thereof
7) previous treatment with immunosuppressive agents and/or steroids excluding local effects
8) simultaneous participation in another interventional trial and/or a clinical trial within the previous 3 months before enrolment in this trial
9) history of participation in studies investigating the transplant of clinical trial products;
10) pregnant females, those lactating, and those unwilling to prevent pregnancy during the study period
11) individuals judged by the attending physician to be unfit or not suitable for the study

Both

Peripheral nerve injury distal to the wrist joint that cannot be sutured directly

Bio 3D nerve conduit graft to a defect of a peripheral nerve

Peripheral nerve, nerve regeneration, artificial nerve, autologous nerve graft, 3D nerve conduit

Tlansplantation, Surgery, Therapy

Q000637

Safety
Incidence of adverse events that cannot be ruled out as related to investigational products or transplantation of investigational products, and skin tissue harvesting

Effectiveness
1)Sensory functional results by SW test 48 weeks after the surgery
2)Sensory functional results by the two-point identification test 48 weeks after the surgery
1:Static two-point discrimination
2:Dynamic two-point discrimination

+81-75-751-4389

Mar. 25, 2020

No

none